Brand Protocol

The PureResponseTM Immune Protocol – Innate Immunity & Th1 Support Protocol (Left Loop)


The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload this template

The PureResponseTM Immune Protocol – Innate Immunity & Th1 Support Protocol (Left Loop)

Developed with Samuel F. Yanuck, D.C., FACFN, FIAMA+

Protocol Objective:

This protocol is intended for patients in need of support for both innate immunity and Th1 response. These patients are often characterized by altered immune surveillance and intestinal microbial balance. The products in this protocol are designed to promote cytokine balance and cell-mediated immunity (including natural killer cell and macrophage activity), as well as healthy Th1 cell status.‡


Innate Immune Support

1 capsule, once to twice per day, with or between meals, minimum 3 months

Download the US product monograph

Th1 Support

2 capsules, once to twice per day, with or between meals, minimum 3 months

Download the US product monograph

Balanced Immune

1 capsule, once to twice per day, with or between meals, minimum 3 months

Download the US product monograph

Additional Support Products:

  • Black Currant Seed Oil
  • NAC 600 mg
  • Liposomal Glutathione

Acute/Intensive Support for Self-tissue Response:

  • Consider increasing the dose of Innate Immune Support, Th1 Support, and Balanced Immune and/or introducing one or more of the following:
    • Th2 Modulator
    • Liposomal Glutathione
    • Vitamin D3



When applying the PureResponseTM Immune Protocols, supplementation with Th1 Support will not be appropriate for a small subset of patients. This small subset is typically identified by a recent, vigorous onset of self-tissue response, most often associated with the need for joint support or joint comfort. Labs may indicate a need to modulate monocyte response (percentage). For these patients, supplementation with Balanced Immune may be indicated.




The initial application of the PureResponseTM Immune Protocols is intended to be three to six months. After this period, product dosages may be lowered or discontinued if appropriate, based on patient status, Cogence Brief Immunological Assessment results, lab test results, and the clinician’s impression of the ongoing need for support.

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.